Increased Prevalence of Rare Copy Number Variants in Treatment-Resistant Psychosis

• Published in: Schizophrenia bulletin Vol. 49; no. 4; pp. 881 - 892
• Main Authors: Farrell, Martilias, Dietterich, Tyler E, Harner, Matthew K, Bruno, Lisa M, Filmyer, Dawn M, Shaughnessy, Rita A, Lichtenstein, Maya L, Britt, Allison M, Biondi, Tamara F, Crowley, James J, Lázaro-Muñoz, Gabriel, Forsingdal, Annika E, Nielsen, Jacob, Didriksen, Michael, Berg, Jonathan S, Wen, Jia, Szatkiewicz, Jin, Mary Xavier, Rose, Sullivan, Patrick F, Josiassen, Richard C
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 04.07.2023
• Subjects: Cohort Studies; DNA Copy Number Variations - genetics; Genetic Predisposition to Disease; Humans; Medicin och hälsovetenskap; Prevalence; Psychotic Disorders - drug therapy; Psychotic Disorders - epidemiology; Psychotic Disorders - genetics; Regular; Schizophrenia - drug therapy; Schizophrenia - epidemiology; Schizophrenia - genetics; rare variants; treatment-resistant psychosis; 16p11.2 duplication; ultra-TRS; copy number variants; schizophrenia; neurodevelopmental disorders; 15q11.2-q13.1 duplication
• ISSN: 0586-7614; 1745-1701; 1745-1701
• DOI: 10.1093/schbul/sbac175

Abstract Background It remains unknown why ~30% of patients with psychotic disorders fail to respond to treatment. Previous genomic investigations of treatment-resistant psychosis have been inconclusive, but some evidence suggests a possible link between rare disease-associated copy number variants (CNVs) and worse clinical outcomes in schizophrenia. Here, we identified schizophrenia-associated CNVs in patients with treatment-resistant psychotic symptoms and then compared the prevalence of these CNVs to previously published schizophrenia cases not selected for treatment resistance. Methods CNVs were identified using chromosomal microarray (CMA) and whole exome sequencing (WES) in 509 patients with treatment-resistant psychosis (a lack of clinical response to ≥3 adequate antipsychotic medication trials over at least 5 years of psychiatric hospitalization). Prevalence of schizophrenia-associated CNVs in this sample was compared to that in a previously published large schizophrenia cohort study. Results Integrating CMA and WES data, we identified 47 cases (9.2%) with at least one CNV of known or possible neuropsychiatric risk. 4.7% (n = 24) carried a known neurodevelopmental risk CNV. The prevalence of well-replicated schizophrenia-associated CNVs was 4.1%, with duplications of the 16p11.2 and 15q11.2-q13.1 regions, and deletions of the 22q11.2 chromosomal region as the most frequent CNVs. Pairwise loci-based analysis identified duplications of 15q11.2-q13.1 to be independently associated with treatment resistance. Conclusions These findings suggest that CNVs may uniquely impact clinical phenotypes beyond increasing risk for schizophrenia and may potentially serve as biological entry points for studying treatment resistance. Further investigation will be necessary to elucidate the spectrum of phenotypic characteristics observed in adult psychiatric patients with disease-associated CNVs.